Exact Mass: 389.16002
Exact Mass Matches: 389.16002
Found 188 metabolites which its exact mass value is equals to given mass value 389.16002
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Diphemanil Methylsulfate
C21H27NO4S (389.1660702000001)
C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics Diphemanil methylsulfate is a quaternary ammonium anticholinergic. It binds muscarinic acetycholine receptors and thereby decreases secretory excretion of stomach acids as well as saliva and sweat. IC50 value: Target: mAChR Diphemanil Methylsulfate exerts its action by primarily binding the muscarinic M3 receptor. M3 receptors are located in the smooth muscles of the blood vessels, as well as in the lungs. This means they cause vasodilation and bronchoconstriction. They are also in the smooth muscles of the gastrointestinal tract (GIT), which help in increasing intestinal motility and dilating sphincters. The M3 receptors are also located in many glands which help to stimulate secretion in salivary glands and other glands of the body.
2-(Furan-2-yl)-7-(3-(4-methoxyphenyl)propyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine
D018377 - Neurotransmitter Agents > D058905 - Purinergic Agents > D058914 - Purinergic Antagonists SCH442416 is a potent, selective and brain-penetrant antagonist of adenosine A2A receptor (A2AR), with Kis of 0.048 and 0.5 nM for human and rat A2AR respectively. SCH442416 displays more than 23000-fold selectivity over A1R, A2BR, and A3R (Ki=1111, 10000, and 10000 nM, respectively). SCH442416 can be used for imaging of adenosine A2A receptors in rat and primate brain[1][2].
Reproterol
R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03C - Adrenergics for systemic use > R03CC - Selective beta-2-adrenoreceptor agonists R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03A - Adrenergics, inhalants > R03AC - Selective beta-2-adrenoreceptor agonists D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents
Ala Ala Asp Asn
Ala Ala Asn Asp
Ala Asp Ala Asn
Ala Asp Gly Gln
Ala Asp Asn Ala
Ala Asp Gln Gly
Ala Glu Gly Asn
Ala Glu Asn Gly
Ala Gly Asp Gln
Ala Gly Glu Asn
Ala Gly Gly Trp
Ala Gly Asn Glu
Ala Gly Gln Asp
Ala Gly Trp Gly
Ala Asn Ala Asp
Ala Asn Asp Ala
Ala Asn Glu Gly
Ala Asn Gly Glu
Ala Gln Asp Gly
Ala Gln Gly Asp
Ala Trp Gly Gly
Asp Ala Ala Asn
Asp Ala Gly Gln
Asp Ala Asn Ala
Asp Ala Gln Gly
Asp Gly Ala Gln
Asp Gly Gln Ala
Asp Asn Ala Ala
Asp Gln Ala Gly
Asp Gln Gly Ala
Glu Ala Gly Asn
Glu Ala Asn Gly
Glu Gly Ala Asn
Glu Gly Gly Gln
Glu Gly Asn Ala
Glu Gly Gln Gly
Glu Asn Ala Gly
Glu Asn Gly Ala
Glu Gln Gly Gly
Gly Ala Asp Gln
Gly Ala Glu Asn
Gly Ala Gly Trp
Gly Ala Asn Glu
Gly Ala Gln Asp
Gly Ala Trp Gly
Gly Asp Ala Gln
Gly Asp Gln Ala
Gly Glu Ala Asn
Gly Glu Gly Gln
Gly Glu Asn Ala
Gly Glu Gln Gly
Gly Gly Ala Trp
Gly Gly Glu Gln
Gly Gly Gln Glu
Gly Gly Trp Ala
Gly Asn Ala Glu
Gly Asn Glu Ala
Gly Gln Ala Asp
Gly Gln Asp Ala
Gly Gln Glu Gly
Gly Gln Gly Glu
Gly Trp Ala Gly
Gly Trp Gly Ala
Asn Ala Ala Asp
Asn Ala Asp Ala
Asn Ala Glu Gly
Asn Ala Gly Glu
Asn Asp Ala Ala
Asn Glu Ala Gly
Asn Glu Gly Ala
Asn Gly Ala Glu
Asn Gly Glu Ala
Gln Ala Asp Gly
Gln Ala Gly Asp
Gln Asp Ala Gly
Gln Asp Gly Ala
Gln Glu Gly Gly
Gln Gly Ala Asp
Gln Gly Asp Ala
Gln Gly Glu Gly
Gln Gly Gly Glu
Trp Ala Gly Gly
Trp Gly Ala Gly
Trp Gly Gly Ala
(6E)-2,4-ditert-butyl-6-[(4-chloro-2-nitrophenyl)hydrazinylidene]cyclohexa-2,4-dien-1-one
ISO-PROPYL 2-ACETAMIDO-3,4,6-TRI-O-ACETYL-2-DEOXY-BETA-D-GLUCOPYRANOSIDE
C17H27NO9 (389.16857319999997)
N-[3-(2-Chloro-10H-phenothiazin-10-yl)propyl]-N,N,N-trimethyl-1,3-propanediamine
C21H28ClN3S (389.1692358000001)
Venglustat
D004791 - Enzyme Inhibitors C471 - Enzyme Inhibitor Ibiglustat (Venglustat) is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease[1][2].
(2S)-2-(3-carbamimidamidophenyl)-3-[hydroxy(3-phenylpropyl)phosphoryl]propanoic acid
C19H24N3O4P (389.15043540000005)
Reproterol
R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03C - Adrenergics for systemic use > R03CC - Selective beta-2-adrenoreceptor agonists R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03A - Adrenergics, inhalants > R03AC - Selective beta-2-adrenoreceptor agonists D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents
(2E,4E)-5-[(1R,7S,8R,9R)-7-hydroxy-4-methoxycarbonyl-9-methyl-11-oxo-10-oxatricyclo[6.3.2.01,7]tridec-3-en-9-yl]-2-methylpenta-2,4-dienoate
L-alanyl-gamma-D-glutamyl-meso-diaminopimelate(1-)
2-[[2-[(1-Cyclohexyl-5-tetrazolyl)thio]-1-oxoethyl]amino]benzoic acid ethyl ester
C18H23N5O3S (389.15215280000007)
3-(4-fluorophenyl)-N-[3-(1-imidazolyl)propyl]-1-phenyl-4-pyrazolecarboxamide
3-[2-(2,4-Dimethyl-3-furanyl)-2-oxoethyl]-3-hydroxy-1-(2-phenylethyl)-2-indolone
C24H23NO4 (389.16269980000004)
5-[[1-(2-Methoxyphenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indol-2-yl]methyl]-2-methylthiazole
C23H23N3OS (389.15617480000003)
(1R,5S)-N-(3-fluorophenyl)-7-[4-(5-pyrimidinyl)phenyl]-3,6-diazabicyclo[3.1.1]heptane-3-carboxamide
SCH 442416
D018377 - Neurotransmitter Agents > D058905 - Purinergic Agents > D058914 - Purinergic Antagonists SCH442416 is a potent, selective and brain-penetrant antagonist of adenosine A2A receptor (A2AR), with Kis of 0.048 and 0.5 nM for human and rat A2AR respectively. SCH442416 displays more than 23000-fold selectivity over A1R, A2BR, and A3R (Ki=1111, 10000, and 10000 nM, respectively). SCH442416 can be used for imaging of adenosine A2A receptors in rat and primate brain[1][2].
AKT-IN-6
AKT-IN-6 (Example 13) is a potent Akt inhibitor. AKT-IN-6 inhibits Akt1, Akt2 and Akt3 with IC50s < 500nM, respectively. (patent WO2013056015A1).